SK5942002A3 - Isoxazole derivatives to be used as phosphodiesterase vii inhibitors, use thereof and pharmaceutical composition comprising the same - Google Patents
Isoxazole derivatives to be used as phosphodiesterase vii inhibitors, use thereof and pharmaceutical composition comprising the same Download PDFInfo
- Publication number
- SK5942002A3 SK5942002A3 SK594-2002A SK5942002A SK5942002A3 SK 5942002 A3 SK5942002 A3 SK 5942002A3 SK 5942002 A SK5942002 A SK 5942002A SK 5942002 A3 SK5942002 A3 SK 5942002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- isoxazole
- vinyl
- formula
- cyano
- phosphodiesterase vii
- Prior art date
Links
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 title claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 10
- 150000002545 isoxazoles Chemical class 0.000 title claims description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 32
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 206010040047 Sepsis Diseases 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 208000030507 AIDS Diseases 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000001132 Osteoporosis Diseases 0.000 claims description 6
- 206010052779 Transplant rejections Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 230000000172 allergic effect Effects 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 230000004614 tumor growth Effects 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 5
- 208000026139 Memory disease Diseases 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 206010006451 bronchitis Diseases 0.000 claims description 5
- 208000007451 chronic bronchitis Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 230000009401 metastasis Effects 0.000 claims description 5
- 208000017520 skin disease Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 7
- 239000002904 solvent Substances 0.000 abstract description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 14
- 229920002554 vinyl polymer Polymers 0.000 description 14
- -1 methylene cyclopentyl Chemical group 0.000 description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 11
- 239000000243 solution Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 208000016261 weight loss Diseases 0.000 description 7
- 230000004580 weight loss Effects 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LSIAMBSCPZWFCG-UHFFFAOYSA-N 3-(2-chlorophenyl)-5-[2-(3,4-dimethylanilino)ethenyl]-1,2-oxazole-4-carbonitrile Chemical compound C1=C(C)C(C)=CC=C1NC=CC1=C(C#N)C(C=2C(=CC=CC=2)Cl)=NO1 LSIAMBSCPZWFCG-UHFFFAOYSA-N 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000097929 Porphyria Species 0.000 description 2
- 208000010642 Porphyrias Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 description 1
- 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 description 1
- RMOILXCEWVVXHG-UHFFFAOYSA-N 3-(2,6-dichlorophenyl)-5-[2-(2,4-difluoroanilino)ethenyl]-1,2-oxazole-4-carbonitrile Chemical compound FC1=CC(F)=CC=C1NC=CC1=C(C#N)C(C=2C(=CC=CC=2Cl)Cl)=NO1 RMOILXCEWVVXHG-UHFFFAOYSA-N 0.000 description 1
- BYGYINCQVTVXKJ-UHFFFAOYSA-N 3-(2,6-dichlorophenyl)-5-[2-(2,4-dimethoxyanilino)ethenyl]-1,2-oxazole-4-carbonitrile Chemical compound COC1=CC(OC)=CC=C1NC=CC1=C(C#N)C(C=2C(=CC=CC=2Cl)Cl)=NO1 BYGYINCQVTVXKJ-UHFFFAOYSA-N 0.000 description 1
- FVARQXMNMCDWDV-UHFFFAOYSA-N 3-(2,6-dichlorophenyl)-5-[2-(2-phenylanilino)ethenyl]-1,2-oxazole-4-carbonitrile Chemical compound ClC1=CC=CC(Cl)=C1C1=NOC(C=CNC=2C(=CC=CC=2)C=2C=CC=CC=2)=C1C#N FVARQXMNMCDWDV-UHFFFAOYSA-N 0.000 description 1
- QRCXOIVDURCPLT-UHFFFAOYSA-N 3-(2,6-dichlorophenyl)-5-[2-(4-methoxyanilino)ethenyl]-1,2-oxazole-4-carbonitrile Chemical compound C1=CC(OC)=CC=C1NC=CC1=C(C#N)C(C=2C(=CC=CC=2Cl)Cl)=NO1 QRCXOIVDURCPLT-UHFFFAOYSA-N 0.000 description 1
- HQXQJJCBTYNUTC-UHFFFAOYSA-N 3-(2,6-dichlorophenyl)-5-[2-(4-methylanilino)ethenyl]-1,2-oxazole-4-carbonitrile Chemical compound C1=CC(C)=CC=C1NC=CC1=C(C#N)C(C=2C(=CC=CC=2Cl)Cl)=NO1 HQXQJJCBTYNUTC-UHFFFAOYSA-N 0.000 description 1
- YZAKGFQAPDMGRC-UHFFFAOYSA-N 3-(2-chlorophenyl)-5-[2-(3,5-dichloroanilino)ethenyl]-1,2-oxazole-4-carbonitrile Chemical compound ClC1=CC(Cl)=CC(NC=CC2=C(C(=NO2)C=2C(=CC=CC=2)Cl)C#N)=C1 YZAKGFQAPDMGRC-UHFFFAOYSA-N 0.000 description 1
- INZYHDANQDPSOH-UHFFFAOYSA-N 3-(2-chlorophenyl)-5-[2-(4-fluoroanilino)ethenyl]-1,2-oxazole-4-carbonitrile Chemical compound C1=CC(F)=CC=C1NC=CC1=C(C#N)C(C=2C(=CC=CC=2)Cl)=NO1 INZYHDANQDPSOH-UHFFFAOYSA-N 0.000 description 1
- QKYYXBRSPXSIEI-UHFFFAOYSA-N 3-(2-chlorophenyl)-5-[2-(4-methoxyanilino)ethenyl]-1,2-oxazole-4-carbonitrile Chemical compound C1=CC(OC)=CC=C1NC=CC1=C(C#N)C(C=2C(=CC=CC=2)Cl)=NO1 QKYYXBRSPXSIEI-UHFFFAOYSA-N 0.000 description 1
- NUEGHRSQZZTMNV-UHFFFAOYSA-N 3-phenyl-5-[2-[3-(trifluoromethoxy)anilino]ethenyl]-1,2-oxazole-4-carbonitrile Chemical compound FC(F)(F)OC1=CC=CC(NC=CC2=C(C(=NO2)C=2C=CC=CC=2)C#N)=C1 NUEGHRSQZZTMNV-UHFFFAOYSA-N 0.000 description 1
- OUDASKLYEJGDGK-UHFFFAOYSA-N 4-[2-(4-cyano-3-phenyl-1,2-oxazol-5-yl)ethenylamino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC=CC1=C(C#N)C(C=2C=CC=CC=2)=NO1 OUDASKLYEJGDGK-UHFFFAOYSA-N 0.000 description 1
- WJLJRIUNTUFTOV-UHFFFAOYSA-N 4-[2-[3-(2,6-dichlorophenyl)-4-methoxycarbonyl-1,2-oxazol-5-yl]ethenylamino]benzoic acid Chemical compound O1N=C(C=2C(=CC=CC=2Cl)Cl)C(C(=O)OC)=C1C=CNC1=CC=C(C(O)=O)C=C1 WJLJRIUNTUFTOV-UHFFFAOYSA-N 0.000 description 1
- RDSJFPBXMPCONF-UHFFFAOYSA-N 4-[2-[3-(2-chloro-6-fluorophenyl)-4-cyano-1,2-oxazol-5-yl]ethenylamino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC=CC1=C(C#N)C(C=2C(=CC=CC=2F)Cl)=NO1 RDSJFPBXMPCONF-UHFFFAOYSA-N 0.000 description 1
- XGQJEIMAAQBFET-UHFFFAOYSA-N 4-[2-[3-(2-chlorophenyl)-4-cyano-1,2-oxazol-5-yl]ethenylamino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC=CC1=C(C#N)C(C=2C(=CC=CC=2)Cl)=NO1 XGQJEIMAAQBFET-UHFFFAOYSA-N 0.000 description 1
- TUUKNZOJDDSAMY-UHFFFAOYSA-N 4-[2-[4-cyano-3-(2,6-dichlorophenyl)-1,2-oxazol-5-yl]ethenylamino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC=CC1=C(C#N)C(C=2C(=CC=CC=2Cl)Cl)=NO1 TUUKNZOJDDSAMY-UHFFFAOYSA-N 0.000 description 1
- VQIJXBHEVUQNRH-UHFFFAOYSA-N 5-(2-amino-2-phenylethenyl)-n-methyl-3-phenyl-1,2-oxazole-4-carboxamide Chemical compound O1N=C(C=2C=CC=CC=2)C(C(=O)NC)=C1C=C(N)C1=CC=CC=C1 VQIJXBHEVUQNRH-UHFFFAOYSA-N 0.000 description 1
- LGQUPVFWRHJHCB-UHFFFAOYSA-N 5-[2-(2,4-dichloroanilino)ethenyl]-3-(2,6-dichlorophenyl)-1,2-oxazole-4-carbonitrile Chemical compound ClC1=CC(Cl)=CC=C1NC=CC1=C(C#N)C(C=2C(=CC=CC=2Cl)Cl)=NO1 LGQUPVFWRHJHCB-UHFFFAOYSA-N 0.000 description 1
- JJHFKNCQWYQPNX-UHFFFAOYSA-N 5-[2-(2,4-difluoroanilino)ethenyl]-3-phenyl-1,2-oxazole-4-carbonitrile Chemical compound FC1=CC(F)=CC=C1NC=CC1=C(C#N)C(C=2C=CC=CC=2)=NO1 JJHFKNCQWYQPNX-UHFFFAOYSA-N 0.000 description 1
- ACOZVZSUNBNUCP-UHFFFAOYSA-N 5-[2-(3,5-dichloroanilino)ethenyl]-3-(2,6-dichlorophenyl)-1,2-oxazole-4-carbonitrile Chemical compound ClC1=CC(Cl)=CC(NC=CC2=C(C(=NO2)C=2C(=CC=CC=2Cl)Cl)C#N)=C1 ACOZVZSUNBNUCP-UHFFFAOYSA-N 0.000 description 1
- GOVZRNVRLFZAHZ-UHFFFAOYSA-N 5-[2-(3-chloroanilino)ethenyl]-3-(2-chlorophenyl)-1,2-oxazole-4-carbonitrile Chemical compound ClC1=CC=CC(NC=CC2=C(C(=NO2)C=2C(=CC=CC=2)Cl)C#N)=C1 GOVZRNVRLFZAHZ-UHFFFAOYSA-N 0.000 description 1
- ZHHGIXWXKUAPIE-UHFFFAOYSA-N 5-[2-(3-methylsulfanylanilino)ethenyl]-3-phenyl-1,2-oxazole-4-carbonitrile Chemical compound CSC1=CC=CC(NC=CC2=C(C(=NO2)C=2C=CC=CC=2)C#N)=C1 ZHHGIXWXKUAPIE-UHFFFAOYSA-N 0.000 description 1
- OUHXPWSFCZDZTN-UHFFFAOYSA-N 5-[2-(4-chloroanilino)ethenyl]-3-(2-chloro-6-fluorophenyl)-1,2-oxazole-4-carbonitrile Chemical compound FC1=CC=CC(Cl)=C1C1=NOC(C=CNC=2C=CC(Cl)=CC=2)=C1C#N OUHXPWSFCZDZTN-UHFFFAOYSA-N 0.000 description 1
- RHXYZIQSFPAUTJ-UHFFFAOYSA-N 5-[2-(4-chloroanilino)ethenyl]-3-(2-chlorophenyl)-1,2-oxazole-4-carbonitrile Chemical compound C1=CC(Cl)=CC=C1NC=CC1=C(C#N)C(C=2C(=CC=CC=2)Cl)=NO1 RHXYZIQSFPAUTJ-UHFFFAOYSA-N 0.000 description 1
- QGQHNZOYGOYNMH-UHFFFAOYSA-N 5-[2-(4-methoxyanilino)ethenyl]-3-phenyl-1,2-oxazole-4-carbonitrile Chemical compound C1=CC(OC)=CC=C1NC=CC1=C(C#N)C(C=2C=CC=CC=2)=NO1 QGQHNZOYGOYNMH-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- SCGCBSSEFQGUHC-UHFFFAOYSA-N methyl 3-(2-chloro-6-fluorophenyl)-5-[2-(2,4-dichloroanilino)ethenyl]-1,2-oxazole-4-carboxylate Chemical compound O1N=C(C=2C(=CC=CC=2F)Cl)C(C(=O)OC)=C1C=CNC1=CC=C(Cl)C=C1Cl SCGCBSSEFQGUHC-UHFFFAOYSA-N 0.000 description 1
- BNSTUYYQPNYPMJ-UHFFFAOYSA-N methyl 3-(2-chloro-6-fluorophenyl)-5-[2-(4-methoxyanilino)ethenyl]-1,2-oxazole-4-carboxylate Chemical compound O1N=C(C=2C(=CC=CC=2F)Cl)C(C(=O)OC)=C1C=CNC1=CC=C(OC)C=C1 BNSTUYYQPNYPMJ-UHFFFAOYSA-N 0.000 description 1
- UFZQAGSBXXYFQV-UHFFFAOYSA-N methyl 5-(2-anilinoethenyl)-3-phenyl-1,2-oxazole-4-carboxylate Chemical compound O1N=C(C=2C=CC=CC=2)C(C(=O)OC)=C1C=CNC1=CC=CC=C1 UFZQAGSBXXYFQV-UHFFFAOYSA-N 0.000 description 1
- VONRBYSTGVWPSS-UHFFFAOYSA-N methyl 5-[2-(4-chloroanilino)ethenyl]-3-(2,6-dichlorophenyl)-1,2-oxazole-4-carboxylate Chemical compound O1N=C(C=2C(=CC=CC=2Cl)Cl)C(C(=O)OC)=C1C=CNC1=CC=C(Cl)C=C1 VONRBYSTGVWPSS-UHFFFAOYSA-N 0.000 description 1
- UDMYGPIXYJINMQ-UHFFFAOYSA-N methyl 5-[2-(4-chloroanilino)ethenyl]-3-(2-chloro-6-fluorophenyl)-1,2-oxazole-4-carboxylate Chemical compound O1N=C(C=2C(=CC=CC=2F)Cl)C(C(=O)OC)=C1C=CNC1=CC=C(Cl)C=C1 UDMYGPIXYJINMQ-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19953024A DE19953024A1 (de) | 1999-11-04 | 1999-11-04 | Isoxazolderivate als Phosphodiesterase VII-Hemmer |
| PCT/EP2000/010239 WO2001032175A1 (fr) | 1999-11-04 | 2000-10-18 | Derives d'isoxazol utilises comme inhibiteurs vii de phosphodiesterase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK5942002A3 true SK5942002A3 (en) | 2002-09-10 |
Family
ID=7927860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK594-2002A SK5942002A3 (en) | 1999-11-04 | 2000-10-18 | Isoxazole derivatives to be used as phosphodiesterase vii inhibitors, use thereof and pharmaceutical composition comprising the same |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6531498B1 (fr) |
| EP (1) | EP1225896B1 (fr) |
| JP (1) | JP2003513042A (fr) |
| KR (1) | KR20020047329A (fr) |
| CN (1) | CN1384744A (fr) |
| AR (1) | AR026350A1 (fr) |
| AT (1) | ATE300945T1 (fr) |
| AU (1) | AU781607B2 (fr) |
| BR (1) | BR0015333A (fr) |
| CA (1) | CA2389647C (fr) |
| CZ (1) | CZ20021441A3 (fr) |
| DE (2) | DE19953024A1 (fr) |
| ES (1) | ES2243313T3 (fr) |
| HU (1) | HUP0203187A3 (fr) |
| MX (1) | MXPA02004441A (fr) |
| NO (1) | NO20022123D0 (fr) |
| PL (1) | PL355021A1 (fr) |
| RU (1) | RU2002113746A (fr) |
| SK (1) | SK5942002A3 (fr) |
| WO (1) | WO2001032175A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2255294T3 (es) * | 1998-08-07 | 2006-06-16 | Chiron Corporation | Derivados de isoxazol sustituidos como moduladores del receptor de estrogenos. |
| ES2217956B1 (es) * | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
| US20050107350A1 (en) * | 2003-08-22 | 2005-05-19 | Pharmacia Corporation | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith |
| KR100666052B1 (ko) * | 2004-02-12 | 2007-01-09 | 조극래 | 원적외선이용한 건조장치 |
| PL2272490T3 (pl) * | 2005-07-29 | 2020-05-18 | Basf Se | Stabilizacja produktów do pielęgnacji ciała i stosowanych w gospodarstwach domowych przed rozkładem w wyniku promieniowania uv z zastosowaniem pochodnych merocyjaniny |
| US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| EP2139475B1 (fr) * | 2007-03-27 | 2014-12-17 | Omeros Corporation | Inhibiteurs de PDE7 pour le traitement de troubles du mouvement |
| US20120115849A1 (en) | 2010-11-08 | 2012-05-10 | Demopulos Gregory A | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors |
| US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
| CN104725329B (zh) * | 2015-01-13 | 2017-01-18 | 陕西科技大学 | 一种具有抗肿瘤活性的异恶唑羧酸类化合物及其合成方法 |
| JP7213863B2 (ja) | 2017-07-12 | 2023-01-27 | ダート・ニューロサイエンス・エルエルシー | Ｐｄｅ７阻害剤としての置換ベンゾオキサゾール及びベンゾフラン化合物 |
| EP4572765A1 (fr) | 2022-08-18 | 2025-06-25 | Mitodicure GmbH | Utilisation d'un agent thérapeutique ayant une activité inhibitrice de phosphodiestérase-7 pour le traitement et la prévention de maladies associées à la fatigue, à l'épuisement et/ou à l'intolérance à l'effort chroniques |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2102209C (fr) * | 1991-05-01 | 1997-11-18 | Takashi Shindo | Nouveau derive de l'isoxazole et sel de ce dernier |
| CZ283564B6 (cs) | 1993-11-26 | 1998-05-13 | Pfizer Inc. | 3-Aryl-2-isoxazolin-5-hydroxamové kyseliny a farmaceutické prostředky na jejich bázi |
| US5686434A (en) * | 1993-11-26 | 1997-11-11 | Pfizer Inc. | 3-aryl-2-isoxazolines as antiinflammatory agents |
-
1999
- 1999-11-04 DE DE19953024A patent/DE19953024A1/de not_active Withdrawn
-
2000
- 2000-10-18 RU RU2002113746/15A patent/RU2002113746A/ru unknown
- 2000-10-18 DE DE50010885T patent/DE50010885D1/de not_active Expired - Lifetime
- 2000-10-18 BR BR0015333-8A patent/BR0015333A/pt not_active Application Discontinuation
- 2000-10-18 PL PL00355021A patent/PL355021A1/xx unknown
- 2000-10-18 HU HU0203187A patent/HUP0203187A3/hu unknown
- 2000-10-18 CN CN00814943A patent/CN1384744A/zh active Pending
- 2000-10-18 ES ES00971393T patent/ES2243313T3/es not_active Expired - Lifetime
- 2000-10-18 EP EP00971393A patent/EP1225896B1/fr not_active Expired - Lifetime
- 2000-10-18 US US10/129,270 patent/US6531498B1/en not_active Expired - Fee Related
- 2000-10-18 CA CA2389647A patent/CA2389647C/fr not_active Expired - Fee Related
- 2000-10-18 KR KR1020027005728A patent/KR20020047329A/ko not_active Withdrawn
- 2000-10-18 SK SK594-2002A patent/SK5942002A3/sk not_active Application Discontinuation
- 2000-10-18 JP JP2001534380A patent/JP2003513042A/ja active Pending
- 2000-10-18 AU AU10262/01A patent/AU781607B2/en not_active Ceased
- 2000-10-18 AT AT00971393T patent/ATE300945T1/de not_active IP Right Cessation
- 2000-10-18 CZ CZ20021441A patent/CZ20021441A3/cs unknown
- 2000-10-18 WO PCT/EP2000/010239 patent/WO2001032175A1/fr not_active Ceased
- 2000-11-03 AR ARP000105799A patent/AR026350A1/es unknown
-
2002
- 2002-05-03 MX MXPA02004441A patent/MXPA02004441A/es unknown
- 2002-05-03 NO NO20022123A patent/NO20022123D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2389647A1 (fr) | 2001-05-10 |
| RU2002113746A (ru) | 2004-01-10 |
| MXPA02004441A (es) | 2004-09-10 |
| PL355021A1 (en) | 2004-03-22 |
| KR20020047329A (ko) | 2002-06-21 |
| AU1026201A (en) | 2001-05-14 |
| CN1384744A (zh) | 2002-12-11 |
| AU781607B2 (en) | 2005-06-02 |
| CA2389647C (fr) | 2010-08-10 |
| AR026350A1 (es) | 2003-02-05 |
| HUP0203187A2 (hu) | 2003-01-28 |
| EP1225896A1 (fr) | 2002-07-31 |
| BR0015333A (pt) | 2002-07-09 |
| HUP0203187A3 (en) | 2004-12-28 |
| WO2001032175A1 (fr) | 2001-05-10 |
| US6531498B1 (en) | 2003-03-11 |
| EP1225896B1 (fr) | 2005-08-03 |
| ES2243313T3 (es) | 2005-12-01 |
| ATE300945T1 (de) | 2005-08-15 |
| NO20022123L (no) | 2002-05-03 |
| CZ20021441A3 (cs) | 2002-07-17 |
| NO20022123D0 (no) | 2002-05-03 |
| DE50010885D1 (de) | 2005-09-08 |
| DE19953024A1 (de) | 2001-05-10 |
| JP2003513042A (ja) | 2003-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK5952002A3 (en) | Pyrrole derivatives as phosphodiesterase vii inhibitor, the use thereof and pharmaceutical composition comprising the same | |
| AU775993B2 (en) | Imidazopyridine derivatives as phosphodiesterase VII inhibitors | |
| EP1036078B1 (fr) | Thienopyrimidines | |
| JP4819272B2 (ja) | ホスホジエステラーゼｖｉｉ阻害剤として用いられるイミダゾール化合物 | |
| US7491742B2 (en) | Imidazole derivatives as phosphodiesterase VII inhibitors | |
| EP1084125B1 (fr) | Thienopyrimidines condensees a effet inhibiteur de la phosphodiesterase v | |
| SK5942002A3 (en) | Isoxazole derivatives to be used as phosphodiesterase vii inhibitors, use thereof and pharmaceutical composition comprising the same | |
| SK17632002A3 (sk) | Derivát 5-aminoalkylpyrazolo[4,4-d]pyrimidínu, spôsob jeho prípravy, jeho použitie a liečivo, ktoré ho obsahuje | |
| SK4922002A3 (en) | Imidazole derivative as phosphodiesterase vii inhibitor, use thereof and pharmaceutical composition containing the same | |
| ZA200204430B (en) | Isoxazole derivatives to be used as phosphodiesterase VII inhibitors. | |
| HK1050366A (en) | Imidazopyridine derivatives used as phosphodiesterase vii inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Refused patent application |